We are live on ! Find out more
SNDX icon

Syndax Pharmaceuticals
SNDX

74 hedge funds and large institutions have $68.9M invested in Syndax Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 25 increasing their positions, 22 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

607% more call options, than puts

Call options by funds: $2.05M | Put options by funds: $290K

14% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 22

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

6% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 16

1% less funds holding

Funds holding: 75 → 74 (-1)

3.38% less ownership

Funds ownership: 65.66% → 62.28% (-3.4%)

44% less capital invested

Capital invested by funds: $124M → $68.9M (-$55.1M)

Holders
74
Holders Change
-1
Holders Change %
-1.33%
% of All Funds
1.65%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
15
Increased
25
Reduced
22
Closed
16
Calls
$2.05M
Puts
$290K
Net Calls
+$1.76M
Net Calls Change
-$2.29M

Top Buyers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
+$4.51M
2
BI
BVF Inc
California
+$4.13M
3
SI
Sofinnova Investments
California
+$970K
4
Bank of America
Bank of America
North Carolina
+$934K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$614K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$3.06M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.82M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.37M
4
O
OrbiMed
New York
-$1.23M
5
BlackRock
BlackRock
New York
-$1M
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
26
Millennium Management
New York
$225K -$3.06M -557,573 -92%
TI
27
Telemetry Investments
New York
$222K +$148K +26,947 +117%
Wells Fargo
28
Wells Fargo
California
$192K +$151K +27,477 +177%
Jacobs Levy Equity Management
29
Jacobs Levy Equity Management
New Jersey
$191K -$115K -20,976 -33%
MA
30
MCF Advisors
Kentucky
$169K +$208K +38,000 New
Citadel Advisors
31
Citadel Advisors
Florida
$156K -$126K -23,048 -40%
Charles Schwab
32
Charles Schwab
California
$129K +$25.8K +4,700 +19%
TA
33
Teachers Advisors
New York
$113K – – –
California State Teachers Retirement System (CalSTRS)
34
California State Teachers Retirement System (CalSTRS)
California
$101K – – –
RJA
35
Raymond James & Associates
Florida
$98K +$121K +22,000 New
OC
36
Oppenheimer & Co
New York
$88K +$1.21K +221 +1%
RhumbLine Advisers
37
RhumbLine Advisers
Massachusetts
$86K +$29.3K +5,350 +38%
Squarepoint
38
Squarepoint
New York
$83K +$34.6K +6,303 +51%
Deutsche Bank
39
Deutsche Bank
Germany
$81K -$383K -69,920 -79%
HAG
40
HighPoint Advisor Group
Illinois
$66K -$12.6K -2,300 -18%
ARTA
41
A.R.T. Advisors
New York
$65K +$80.7K +14,717 New
State of Wisconsin Investment Board
42
State of Wisconsin Investment Board
Wisconsin
$64K +$78.9K +14,400 New
AllianceBernstein
43
AllianceBernstein
Tennessee
$61K – – –
Two Sigma Investments
44
Two Sigma Investments
New York
$60K -$52.5K -9,578 -42%
CWG
45
C WorldWide Group
Denmark
$57K -$1.81K -331 -3%
PP
46
Paloma Partners
Connecticut
$56K +$68.5K +12,500 New
TAM
47
Tiverton Asset Management
Delaware
$56K +$69.4K +12,663 New
Group One Trading
48
Group One Trading
Illinois
$55K +$17.8K +3,246 +36%
SIM
49
Spark Investment Management
New York
$55K +$68K +12,400 New
Barclays
50
Barclays
United Kingdom
$52K -$33.3K -6,081 -34%
1
2
3 4

SNDX Hedge Fund Activity: Q4 2018 in Review

74 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q4 2018, worth a combined $68.9M — down 44% from $124M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of SNDX and 15 opened new positions — a net loss of 1 holder — while 22 trimmed existing stakes and 25 added.

The largest buyer was 683 Capital Management, adding an estimated $4.51M. The largest seller was Millennium Management, cutting an estimated $3.06M.

  • 74 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q4 2018, down from 75 in Q3 2018.
  • Funds reported $68.9M of Syndax Pharmaceuticals stock for Q4 2018, down 44% quarter-over-quarter.
  • 15 funds opened new Syndax Pharmaceuticals positions in Q4 2018 and 16 closed out, a net change of -1 holder.
  • The largest Syndax Pharmaceuticals buyer in Q4 2018 was 683 Capital Management, an estimated $4.51M added.
  • The largest Syndax Pharmaceuticals seller in Q4 2018 was Millennium Management, an estimated $3.06M sold.

Based on aggregated 13F filings for Q4 2018.